XVIVO granted method patent for STEEN Solution™ in USA

The United States Patent and Trademark Office (USPTO) has approved a third
patent in the “Preservation and evaluation solution” family.  This means that
STEEN Solution™ and XPS™ have increased patent protection in the USA but also
that XVIVO has patent protection for use of a wide variety of alternative
perfusion solutions for organ perfusion and evaluation. The patent is valid
until the end of 2022.
XVIVO Perfusion already has an approved product patent for STEEN Solution™ and a
broader method patent in the USA. The patent that has now been approved extends
XVIVO’s patent protection for the use of alternative solutions for perfusion and
evaluation of organs before transplantation.

The company’s products STEEN Solution™, XPS™ and the accompanying single-use
products have been approved by the FDA and are being launched in the USA. The
American market is the largest in the world and accounts for just over 40
percent of the number of lung transplants performed.

“Extended patent protection for STEEN Solution™ in the American market is
important in protecting the intangible assets we have built up over many years
in the USA, which is the absolute largest market for lung transplantation in the
world. The method patent for STEEN Solution™ means that XVIVO strengthens its
competitive position in the American market regarding warm perfusion and
evaluation of organs outside the body,” says Dr Magnus Nilsson, CEO of XVIVO
Perfusion AB.

March 20, 2015
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on March 20, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com